ANRO News

In February, 10 IPOs raised a combined $2.0 billion, led by early debuts from a handful of $100+ million offerings. Deal flow was led by healthcare and senior facilities provider American Healthcare REIT (AHR) and Mexican discount grocer BBB Foods (TBBB), which together accounted for nearly two-thirds of the month's proceeds raised. Activity...read more

Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, raised $129 million by offering 8 million shares at $16, the high end of the range of $14 to $16. The company offered 1.3 million more shares than anticipated. Alto Neuroscience is focused on leveraging neurobiology to develop personalized and highly effective treatment...read more

Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, announced terms for its IPO on Monday. The Los Altos, CA-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Alto Neuroscience would command a fully diluted market value of $407...read more

Updated Monday, 1/29. Five listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week. Leading the pack, sports equipment and apparel maker Amer Sports (AS) plans to raise $1.7 billion at an $8.3 billion market cap. The Finland-based company’s portfolio includes major brands like Arc&rsquo...read more